SEARCH

SEARCH BY CITATION

References

  • Anand, S., Ginsberg, J.S., Kearon, C., Gent, M. & Hirsh, J. (1996) The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin. Archives of Internal Medicine, 156, 16771681.
  • Barritt, D.W. & Jordan, S.C. (1960) Anticoagulant drugs in the treatment of pulmonary embolism; a controlled trial. Lancet, 1, 13091312.
  • Bates, S.M. & Weitz, J.I. (2006) The status of new anticoagulants. British Journal of Haematology, 134, 319.
  • Brandjes, D.P., Heijboer, H., Buller, H.R., De Rijk, M., Jagt, H. & Ten Cate, J.W. (1992) Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. New England Journal of Medicine, 327, 14851489.
  • Campbell, H.A. & Link, K.P. (1941) Studies on the hemorrhagic sweet clover disease. IV. The isolation and crystallization of the hemorrhagic agent. Journal of Biological Chemistry, 138, 2133.
  • Campbell, H.A., Roberts, W.L., Smith, W.K. & Link, K.P. (1940) Studies on the hemorrhagic sweet clover disease. I. The preparation of hemorrhagic concentrates. Journal of Biological Chemistry, 136, 4755.
  • Campbell, H.A., Smith, W.K., Roberts, W.L. & Link, K.P. (1941) Studies on the hemorrhagic sweet clover disease. II. The bioassay of hemorrhagic concentrates by following the prothrombin level in the plasma of rabbit blood. Journal of Biological Chemistry, 138, 120.
  • Charles, A.F. & Scott, D.A. (1933a) Studies on heparin I the preparation of heparin. Journal of Biological Chemistry, 102, 425429.
  • Charles, A.F. & Scott, D.A. (1933b) Studies on heparin II heparin in various tissues. Journal of Biological Chemistry, 102, 431435.
  • Charles, A.F. & Scott, D.A. (1933c) Studies on heparin III the purification of heparin. Journal of Biological Chemistry, 102, 437448.
  • Duxbury, B.M. & Poller, L. (2001) The oral anticoagulant saga: past, present, and future. Clinical and Applied Thrombosis/Hemostasis, 7, 269275.
  • Howell, W.H. (1912) The factors concerned in the process of the clotting of blood. Therapeutic Gazette, 36, 9598.
  • Howell, W.H. (1925) The purification of heparin and its presence in blood. American Journal of Physiology, 17, 553562.
  • Howell, W.H. & Holt, E. (1918) Two new factors in blood coagulation – heparin and pro-antithrombin. American Journal of Physiology, 47, 328341.
  • Howell, W.H. & MacDonald, C.H. (1930) Note on the effect of repeated intravascular injections of heparin. Bulletin of Johns Hopkins Hospital, 46, 365368.
  • Hull, R., Hirsh, J., Jay, R., Carter, C., England, C., Gent, M., Turpie, A.G., McLoughlin, D., Dodd, P., Thomas, M., Raskob, G. & Ockelford, P. (1982) Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. New England Journal of Medicine, 307, 16761681.
  • Hull, R.D., Raskob, G.E., Hirsh, J., Jay, R.M., Leclerc, J.R., Geerts, W.H., Rosenbloom, D., Sackett, D.L., Anderson, C., Harrison, L. & Gent, M. (1986) Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. New England Journal of Medicine, 315, 11091114.
  • Jaques, L.B. (1978) Addendum: the discovery of heparin. Seminars in Thrombosis and Hemostasis, 4, 350353.
  • Kirkwood, T.B. (1983) Calibration of reference thromboplastins and standardisation of the prothrombin time ratio. Thrombosis and Haemostasis, 49, 238244.
  • Koopman, M.M., Prandoni, P., Piovella, F., Ockelford, P.A., Brandjes, D.P., Van Der Meer, J., Gallus, A.S., Simonneau, G., Chesterman, C.H., Prins, M.H., Bossuyt, P.M.M., De Haes, H., Van Den Belt, A.G.M., Sagnard, L., D’Azemar, P. & Büller, H.R. (1996) Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. New England Journal of Medicine, 334, 682687.
  • Lange, K., Boyd, L.J. & Loewe, L. (1945) The functional pathology of frostbite and the prevention of gangrene in experimental animals and humans. Science, 102, 151152.
  • Last, J.A. (2002) The missing link: the story of Karl Paul Link. Toxicological Sciences, 66, 46.
  • Levine, M., Gent, M., Hirsh, J., Leclerc, J., Anderson, D., Weitz, J., Ginsberg, J., Turpie, A.G., Demers, C., Kovacs, M., Geerts, W., Kassis, J., Desjardins, L., Cusson, J., Cruickshank, M., Powers, P., Brien, W., Haley, S. & Willanet, A. (1996) A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. New England Journal of Medicine, 334, 677681.
  • Marcum, J.A. (1990) William Henry Howell and Jay McLean: the experimental context for the discovery of heparin. Perspectives in Biology and Medicine, 33, 214230.
  • Marcum, J.A. (1997) The development of heparin in Toronto. Journal of the History of Medicine and Allied Sciences, 52, 310337.
  • Marcum, J.A. (2000) The origin of the dispute over the discovery of heparin. Journal of the History of Medicine and Allied Sciences, 55, 3766.
  • Mason, M.C. (1924) A note on the use of heparin in blood transfusion. Journal of Laboratory and Clinical Medicine, 10, 203206.
  • McLean, J. & Johnson, A.B. (1946) Gangrene following fracture treated with heparin, papaverine, and intermittent venous occlusion. Surgery, 20, 324336.
  • McLean, J., Meyer, B.B.M. & Griffith, J.M. (1941) Heparin in subacute bacterial endocarditis. Reproduction of cases and critical review of the literature. Journal of the American Medical Association, 117, 18701875.
  • Murray, G.D.W. (1940) Heparin in thrombosis and embolism. British Journal of Surgery, 27, 324336.
  • Murray, D.W.G., Jaques, L.B., Perrett, T.S. & Best, C.H. (1937) Heparin and the thrombosis of veins following injury. Surgery, 2, 163187.
  • Overman, R.S., Field, J.B., Baumann, C.A. & Link, K.P. (1942) Studies on the hemorrhagic sweet clover disease. IX. The effect of diet and vitamin k on the hypoprothrombinemia induced by 3,3’-methylenebis(4-hydroxycoumarin) in the rat. The Journal of Nutrition, 23, 589602.
  • Pirmohamed, M. (2006) Warfarin: almost 60 years old and still causing problems. British Journal of Clinical Pharmacology, 62, 509511.
  • Raschke, R.A., Reilly, B.M., Guidry, J.R., Fontana, J.R. & Srinivas, S. (1993) The weight-based heparin dosing nomogram compared with a ‘standard care’ nomogram. A randomized controlled trial [see comments]. Annals of Internal Medicine, 119, 874881.
  • Roderick, L.M. (1929) The pathology of sweet clover disease in cattle. Journal of the American Veterinary Medicine Association, 74, 314325.
  • Roderick, L.M. (1931) A problem in the coagulation of blood: ‘sweet clover disease of cattle’. American Journal of Physiology, 96, 413425.
  • Rutty, C.J. (2000) Miracle Blood Lubricant: Connaught and the Story of Heparin, 1928–1937, http://www.healthheritageresearch.com/Heparin-Conntact9608.html accessed on 5 March 2008. Originally published in CONNTACT August 1996, 9, (4).
  • Schofield, F.W. (1924) The cause of a new disease in cattle stimulating hemorrhagic septicaemia and blackleg. Journal of the American Veterinary Medicine Association, 64, 553575.
  • Stahmann, M.A., Huebner, C.F. & Link, K.P. (1941) Studies on the hemorrhagic sweet clover disease. V. Identification and synthesis of the hemorrhagic agent. Journal of Biological Chemistry, 138, 513527.
  • Ulin, A.W. & Gollub, S. (1964) Posthumous award commemorating the discovery of heparin. New England Journal of Medicine, 270, 466.
  • WHO Expert Committee on Biological Standardization (1983) Thirty-third report. World Health Organization Technical Report Series, 687, 1184.